ALX Oncology to Present at Upcoming Investor Conferences

Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) announced management will present at two investor conferences: a fireside chat at the Jefferies Global Healthcare Conference in London on Nov 19, 2025 at 11:30 AM GMT / 6:30 AM EST, and a fireside chat at the Piper Sandler 37th Annual Global Healthcare Conference in New York on Dec 3, 2025 at 9:30 AM EST.

Both events will be webcast; live links are available in the Investors > Events and Presentations section at www.alxoncology.com. Replays of each webcast will be archived for up to 90 days after the presentation dates.

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37^th Annual Global Healthcare Conference in New York.

The details of the meetings are as follows:

Jefferies Global Healthcare Conference in London

Format: Fireside Chat
Date: Wednesday, November 19, 2025
Time: 11:30 AM GMT / 6:30 AM EST
Location: London, UK
Webcast link: Available here

Piper Sandler 37^th Annual Global Healthcare Conference

Format: Fireside Chat
Date: Wednesday, December 3, 2025
Time: 9:30 AM EST
Location: New York, NY
Webcast link: Available here

The webcasts of the Jefferies London and Piper Sandler fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and Presentations tab. Replays of the webcasts will be archived for up to 90 days following the fireside chat dates.

About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and entered the clinic in a Phase 1 trial in August 2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.

Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com

Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577

FAQ

When is ALX Oncology (ALXO) presenting at the Jefferies Global Healthcare Conference?

ALX Oncology leadership will present on Nov 19, 2025 at 11:30 AM GMT / 6:30 AM EST as a fireside chat.

When is ALX Oncology (ALXO) presenting at the Piper Sandler Global Healthcare Conference?

ALX Oncology leadership will present on Dec 3, 2025 at 9:30 AM EST as a fireside chat in New York.

Will the ALX Oncology (ALXO) conference presentations be webcast?

Yes. Both the Jefferies London and Piper Sandler fireside chats will be webcast and accessible via the company website.

Where can investors watch the ALX Oncology (ALXO) webcasts?

Investors can access live webcasts and replays in Investors > Events and Presentations at www.alxoncology.com.

How long will ALX Oncology (ALXO) keep webcast replays available?

Replays of each webcast will be archived for up to 90 days after the fireside chat date.

Who from ALX Oncology will participate in the conference presentations?

The announcement states that ALX Oncology leadership will participate in both fireside chats.